阿替利珠单抗联合贝伐珠单抗及化疗用于新诊断III/IV期卵巢癌的III期试验
这项多中心安慰剂对照双盲III期试验纳入1301例新诊断III/IV期卵巢癌患者,评估在铂类化疗联合贝伐珠单抗基础上加用阿替利珠单抗的疗效。总生存期中期间析未显示显著获益。结论:当前证据不支持在新诊断卵巢癌中使用免疫检查点抑制剂。
要点
- 总生存期中期间析未显示阿替利珠单抗显著获益。
核心结论
- 当前证据不支持在新诊断卵巢癌中使用免疫检查点抑制剂。
研究设计与样本
- 多中心、安慰剂对照、双盲、随机III期试验(IMagyn050/GOG 3015/ENGOT-OV39,NCT03038100)。
- 纳入1301例新诊断、未经治疗的国际妇产科联盟(FIGO)III或IV期卵巢癌患者。
- 患者按1:1随机接受阿替利珠单抗1200 mg或安慰剂(第1天,周期1-22),联合紫杉醇+卡铂(第1天,周期1-6)及贝伐珠单抗15 mg/kg(第1天,周期2-22)。
- 新辅助化疗患者围手术期省略贝伐珠单抗。
- 共同主要终点为意向治疗人群和PD-L1阳性人群的研究者评估无进展生存期和总生存期。
主要发现
- 总生存期中期间析(不成熟)显示阿替利珠单抗无显著获益。
- 最常见的3或4级不良事件为中性粒细胞减少(阿替利珠单抗组21% vs 安慰剂组21%)、高血压(18% vs 20%)和贫血(12% vs 12%)。
关键数值与推荐
- 无进展生存期和总生存期为共同主要终点,在意向治疗人群和PD-L1阳性人群中评估。
临床怎么用
- 当前证据不支持在新诊断卵巢癌中常规添加免疫检查点抑制剂。
- 该试验结果提示需进一步评估免疫治疗在卵巢癌中的生物标志物及联合策略。
局限性
- 总生存期结果为中期间析且不成熟。
- PD-L1阳性人群的无进展生存期获益为探索性分析,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC). METHODS: This multicenter placebo-controlled double-blind randomized phase III trial (ClinicalTrials.gov identifier: NCT03038100) enrolled patients with newly diagnosed untreated International Federation of Gynecology and Obstetrics (FIGO) stage III or IV OC who either had undergone primary cytoreductive surgery with macroscopic residual disease or were planned to receive neoadjuvant chemotherapy and interval surgery. Patients were stratified by FIGO stage, Eastern Cooperative Oncology Group performance status, tumor immune cell PD-L1 staining, and treatment strategy and randomly assigned 1:1 to receive 3-weekly cycles of atezolizumab 1,200 mg or placebo (day 1, cycles 1-22), with paclitaxel plus carboplatin (day 1, cycles 1-6) plus bevacizumab 15 mg/kg (day 1, cycles 2-22), omitting perioperative bevacizumab in neoadjuvant patients. The co-primary end points were investigator-assessed progression-free survival and overall survival in the intention-to-treat and PD-L1-positive populations. RESULTS: Between March 8, 2017, and March 26, 2019, 1,301 patients were enrolled. The median progression-free survival was 19.5 versus 18.4 months with atezolizumab versus placebo, respectively (hazard ratio, 0.92; 95% CI, 0.79 to 1.07; stratified log-rank P = .28), in the intention-to-treat population and 20.8 versus 18.5 months, respectively (hazard ratio, 0.80; 95% CI, 0.65 to 0.99; P = .038), in the PD-L1-positive population. The interim (immature) overall survival results showed no significant benefit from atezolizumab. The most common grade 3 or 4 adverse events were neutropenia (21% with atezolizumab v 21% with placebo), hypertension (18% v 20%, respectively), and anemia (12% v 12%). CONCLUSION: Current evidence does not support the use of immune checkpoint inhibitors in newly diagnosed OC. Insight from this trial should inform further evaluation of immunotherapy in OC.
引用
- Moore KN, Bookman M, Sehouli J, et al. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021. PMID: 33891472. doi:10.1200/JCO.21.00306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。